The contribution of neutrophils to CNS autoimmunity

Clinical Immunology

Volumn 189, Issue , 2018, Pages 23-28

  Pierson, Emily R ^a   Wagner, Catriona A ^a   Goverman, Joan M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CXCR2; EAE; IL 17; MS; Neutrophils

Indexed keywords

ALPHA CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; CYTOKINE;

ARTICLE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CELL FUNCTION; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DISEASE ACTIVITY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXTRACELLULAR TRAP; HUMAN; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; SPINAL CORD; ANIMAL; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS;

ANIMALS; AUTOIMMUNITY; CENTRAL NERVOUS SYSTEM; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; NEUTROPHIL INFILTRATION; NEUTROPHILS;

EID: 85002892488     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.06.017     Document Type: Article

References (65)

1. Dendrou, C.A., et al. Immunopathology of multiple sclerosis. Nat. Rev. Immunol. 15 (2015), 545–558.
2. Aktas, O., et al. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 33 (2010), 140–152.
3. Bot, J.C., et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 62 (2004), 226–233.
4. Thorpe, J.W., et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 119:Pt 3 (1996), 709–714.
5. Nociti, V., et al. Clinical characteristics, course and prognosis of spinal multiple sclerosis. Spinal Cord 43 (2005), 731–734.
6. Filippi, M., et al. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. AJNR Am. J. Neuroradiol. 18 (1997), 1549–1556.
7. Segal, B.M., Stage-specific immune dysregulation in multiple sclerosis. J. Interf. Cytokine Res. 34 (2014), 633–640.
8. Goverman, J., Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9 (2009), 393–407.
9. van Oosten, B.W., et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR- monitored phase II trial. Neurology 49 (1997), 351–357.
10. Coles, A.J., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359 (2008), 1786–1801.
11. Soulika, A.M., et al. Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J. Neurosci. 29 (2009), 14965–14979.
12. Steinbach, K., et al. Neutrophils amplify autoimmune central nervous system infiltrates by maturing local APCs. J. Immunol. 191 (2013), 4531–4539.
13. Christy, A.L., et al. Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE. J. Autoimmun. 42 (2013), 50–61.
14. Simmons, S.B., et al. Cytokine-regulated neutrophil recruitment is required for brain but not spinal cord inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 193 (2014), 555–563.
15. Rumble, J.M., et al. Neutrophil-related factors as biomarkers in EAE and MS. J. Exp. Med. 212 (2015), 23–35.
16. McColl, S.R., et al. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 161 (1998), 6421–6426.
17. Carlson, T., et al. The Th17-ELR + CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med. 205 (2008), 811–823.
18. Naegele, M., et al. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J. Neuroimmunol. 242 (2012), 60–71.
19. Demirci, S., et al. The clinical significance of the neutrophil-to-lymphocyte ratio in multiple sclerosis. Int. J. Neurol., 2015, 1–7.
20. Chabas, D., et al. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 74 (2010), 399–405.
21. Wright, H.L., et al. Neutrophil function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49 (2010), 1618–1631.
22. Mantovani, A., et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11 (2011), 519–531.
23. Nemeth, T., et al. Neutrophils in animal models of autoimmune disease. Semin. Immunol. 28 (2016), 174–186.
24. Levesque, S.A., et al. Myeloid cell transmigration across the CNS vasculature triggers IL-1beta-driven neuroinflammation during autoimmune encephalomyelitis in mice. J. Exp. Med. 213 (2016), 929–949.
25. Ransohoff, R.M., Brown, M.A., Innate immunity in the central nervous system. J. Clin. Invest. 122 (2012), 1164–1171.
26. Engelhardt, B., Ransohoff, R.M., Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 33 (2012), 579–589.
27. Aube, B., et al. Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases. J. Immunol. 193 (2014), 2438–2454.
28. Rosenberg, G.A., Matrix metalloproteinases in neuroinflammation. Glia 39 (2002), 279–291.
29. Zhou, J., et al. Matrix metalloproteinase expression correlates with virulence following neurotropic mouse hepatitis virus infection. J. Virol. 76 (2002), 7374–7384.
30. Vafadari, B., et al. MMP-9 in translation: from molecule to brain physiology, pathology and therapy. J. Neurochem., 2015.
31. Agrawal, S., et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203 (2006), 1007–1019.
32. Larochelle, C., et al. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett. 585 (2011), 3770–3780.
33. Brinkmann, V., et al. Neutrophil extracellular traps kill bacteria. Science 303 (2004), 1532–1535.
34. Amulic, B., et al. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30 (2012), 459–489.
35. Tillack, K., et al. Gender differences in circulating levels of neutrophil extracellular traps in serum of multiple sclerosis patients. J. Neuroimmunol. 261 (2013), 108–119.
36. Allen, C., et al. Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J. Immunol. 189 (2012), 381–392.
37. Nauseef, W.M., Borregaard, N., Neutrophils at work. Nat. Immunol. 15 (2014), 602–611.
38. Sadik, C.D., et al. Neutrophils cascading their way to inflammation. Trends Immunol. 32 (2011), 452–460.
39. Openshaw, H., et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol. Blood Marrow Transplant. 6 (2000), 563–575.
40. Burt, R.K., et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant. 28 (2001), 1–12.
41. Verda, L., et al. Effect of hematopoietic growth factors on severity of experimental autoimmune encephalomyelitis. Bone Marrow Transplant. 38 (2006), 453–460.
42. Lock, C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–508.
43. Zavala, F., et al. G-CSF therapy of ongoing experimental allergic encephalomyelitis via chemokine- and cytokine-based immune deviation. J. Immunol. 168 (2002), 2011–2019.
44. Lock, C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–508.
45. Kroenke, M.A., et al. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205 (2008), 1535–1541.
46. Roy, M., et al. CXCL1 can be regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during bacterial toxin exposure and encephalomyelitis. J. Neuroinflammation, 9, 2012, 18.
47. Lund, B.T., et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 155 (2004), 161–171.
48. Ishizu, T., et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128 (2005), 988–1002.
49. Bartosik-Psujek, H., Stelmasiak, Z., The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur. J. Neurol. 12 (2005), 49–54.
50. Endoh, M., et al. DM-20, a proteolipid apoprotein, is an encephalitogen of acute and relapsing autoimmune encephalomyelitis in mice. J. Immunol. 137 (1986), 3832–3835.
51. Muller, D.M., et al. A neuropathological analysis of experimental autoimmune encephalomyelitis with predominant brain stem and cerebellar involvement and differences between active and passive induction. Acta Neuropathol. (Berl) 100 (2000), 174–182.
52. Stromnes, I.M., et al. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat. Med. 14 (2008), 337–342.
53. Abromson-Leeman, S., et al. T-cell properties determine disease site, clinical presentation, and cellular pathology of experimental autoimmune encephalomyelitis. Am. J. Pathol. 165 (2004), 1519–1533.
54. Wensky, A.K., et al. IFN-gamma determines distinct clinical outcomes in autoimmune encephalomyelitis. J. Immunol. 174 (2005), 1416–1423.
55. Lees, J.R., et al. Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J. Exp. Med. 205 (2008), 2633–2642.
56. Quintana, A., et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J. Immunol. 183 (2009), 2079–2088.
57. Liu, Y., et al. Preferential recruitment of neutrophils into the cerebellum and brainstem contributes to the atypical experimental autoimmune encephalomyelitis phenotype. J. Immunol. 195 (2015), 841–852.
58. Stoolman, J.S., et al. Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis. J. Immunol. 193 (2014), 564–570.
59. Kroenke, M.A., et al. EAE mediated by a non-IFN-gamma/non-IL-17 pathway. Eur. J. Immunol. 40 (2010), 2340–2348.
60. Bartanusz, V., et al. The blood-spinal cord barrier: morphology and clinical implications. Ann. Neurol. 70 (2011), 194–206.
61. Kroenke, M.A., Segal, B.M., IL-23 modulated myelin-specific T cells induce EAE via an IFNgamma driven, IL-17 independent pathway. Brain Behav. Immun. 25 (2011), 932–937.
62. Iwakura, Y., et al. Functional specialization of interleukin-17 family members. Immunity 34 (2011), 149–162.
63. Miller, N.M., et al. Anti-inflammatory mechanisms of IFN-gamma studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis. Front. Neurosci., 9, 2015, 287.
64. Viegas, N., et al. IFN-gamma production by CD27(+) NK cells exacerbates Listeria monocytogenes infection in mice by inhibiting granulocyte mobilization. Eur. J. Immunol. 43 (2013), 2626–2637.
65. Ding, X., et al. Silencing IFN-gamma binding/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity. J. Immunol. 194 (2015), 4251–4264.